The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1182
May 10, 2004
View Complete Issue         Table of Contents 2019 
Cholesterol Rethink for High-Risk Patients
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cholesterol Rethink for High-Risk Patients
May 10, 2004 (Issue: 1182)
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cholesterol Rethink for High-Risk Patients
Article code: 1182a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.